Related Experiment Video
Updated: Jun 16, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
[Anti-cancer action by PPARgamma ligand]
1Department of General Medicine, Asahikawa Medical College.
Abstract:
Accumulating evidences have shown that thiazolidinediones (TZDs), PPARgamma ligands, could exert anti-cancer actions in several human cancer cells. TZDs are capable to inducing growth inhibition, apoptosis and inhibition of cell invasion, thereby leading to their anti-cancer effects. The growth inhibition was mediated by a cyclin-dependent kinase inhibitor, p27(Kip1), accumulation which is induced by both inhibition of ubiquitylation of p27(Kip1) and reduction of degradation activity of p27(Kip1) by proteasome. In addition, a recent clinical observation has showed a 33% reduction in lung cancer risk among TZD users who have diabetes mellitus compared with nonusers, strongly suggesting TZDs possess clinically relevant actions. These results suggest that TZDs may be novel agents to treat malignant tumor.
More Related Videos
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Related Concept Videos
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
GPCRs Regulate Adenylyl Cylase Activity
Two...